Category: isoxazole

Li, Xiuze published the artcileParecoxib sodium pretreatment reduces myoclonus after etomidate: a prospective, double-blind, randomized clinical trial, Category: isoxazole, the publication is International Journal of Clinical Pharmacology and Therapeutics (2017), 55(7), 601-605, database is CAplus and MEDLINE.

Objective: Myoclonus induced by etomidate during induction of general anesthesia is a common phenomenon. This prospective, randomized, saline-controlled clin. study was performed to evaluate the effect of parecoxib sodium pretreatment on the incidence and severity of etomidate induced myoclonus. Methods: 60 patients, American Society of Anesthesiologists (ASA) phys. status I or II, aged 20 to 60 years, who were scheduled to undergo elective laparoscopic cholecystectomy under general anesthesia, were allocated randomly into one of two groups to receive parecoxib sodium 40 mg i.v. (group P, n = 30) or the same volume of saline (group S, n = 30) 30 min before administration of etomidate (0.3 mg/kg). Myoclonus was assessed on a scale of 0 – 3. Postoperative side effects were recorded. Results: The two groups were comparable with regard to baseline characteristics. The incidence of myoclonus was significantly lower in the parecoxib sodium group (11/30; 37%) than in the saline group (21/30; 70%) (p < 0.05). The severity of myoclonic movements was also significantly reduced by parecoxib sodium (p < 0.05). There were no significant differences between the two groups with respect to postoperative side effects. Conclusions: Pretreatment with i.v. injection of parecoxib sodium 40 mg significantly reduced the incidence and severity of etomidate- induced myoclonus without significant side effects.

International Journal of Clinical Pharmacology and Therapeutics published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Category: isoxazole.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Chen, Fei published the artcileCopper/β-diketone-catalysed N-arylation of carbazoles, Recommanded Product: 9-(4-Fluorophenyl)-9H-carbazole, the publication is RSC Advances (2015), 5(64), 51512-51523, database is CAplus.

A wide range of aryl iodides RC₆H₄I (R = H, 4-Cl, 3-CH₃, 2-Br, etc.) and carbazoles I [R¹ = H, 3-C(CH₃)₃, 3-Br, 2-Br; R² = H, 6-C(CH₃)₃, 7-Br, 6-Br] can be coupled to generate N-arylcarbazoles II in the presence of copper-catalyst. Several com. available ligands such as β-diketone and diamine, are tested in the N-arylation of carbazoles I. The catalytic system generated in situ from an inexpensive copper salt, simple β-diketone and inorganic base efficiently N-arylated the carbazoles I. However, the sterically hindered effect of aryl iodides is evident in this catalytic system. The selectivity of two iodine atoms on the aromatic ring of diiodobenzene R³C₆H₄I (R³ = 4-I, 3-I, 1-Br-2-F) is evaluated in the developed catalytic system. Results showed that the selectivity of diiodobenzene can be tuned by the reaction temperature

RSC Advances published new progress about 57103-14-7. 57103-14-7 belongs to isoxazole, auxiliary class Fused Tricycles,Carbazoles, name is 9-(4-Fluorophenyl)-9H-carbazole, and the molecular formula is C18H12FN, Recommanded Product: 9-(4-Fluorophenyl)-9H-carbazole.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Tao, Sheng published the artcileOne-pot two-step synthesis of N-arylcarbazole-based skeleton, Application In Synthesis of 57103-14-7, the publication is RSC Advances (2016), 6(49), 43250-43260, database is CAplus.

A highly site-selective, one-pot, sequential C-N and C-C bond forming process was developed, affording a carbazole-based skeleton that contains biphenyl and diarylacetylene cores. The success of this process was attributed to the use of fluorinated iodoarenes as the starting material, the fluorine group of which preferentially reacted with carbazole. The subsequent coupling of the intermediate iodinated N-arylcarbazole with arylboronic acid or arylacetylene produced the desired products. The intermediate underwent a Pd-catalyzed Ullmann coupling with excess fluorinated iodoarenes in the absence of arylboronic acid or arylacetylene, resulting in Ullmann coupling products in a one-pot process.

RSC Advances published new progress about 57103-14-7. 57103-14-7 belongs to isoxazole, auxiliary class Fused Tricycles,Carbazoles, name is 9-(4-Fluorophenyl)-9H-carbazole, and the molecular formula is C15H21BO2, Application In Synthesis of 57103-14-7.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Zhu, Daqian published the artcileSynthesis of carbazoles via one-pot copper-catalyzed amine insertion into cyclic diphenyleneiodoniums as a strategy to generate a drug-like chemical library, HPLC of Formula: 57103-14-7, the publication is Advanced Synthesis & Catalysis (2013), 355(11-12), 2172-2178, database is CAplus.

This work showed that diversified carbazoles could be efficiently obtained from a single cyclic diphenyleneiodonium under mild conditions. The reactions catalyzed by Cu(OAc)₂ provided a variety of carbazoles in modest to good yields with a broad range of amines including anilines, aliphatic amines and sulfonamides. Moreover, one of the obtained carbazoles displayed an outstanding ability to protect HT-22 neuronal cells from the damage induced by neurotoxins glutamate and homocysteic acid.

Advanced Synthesis & Catalysis published new progress about 57103-14-7. 57103-14-7 belongs to isoxazole, auxiliary class Fused Tricycles,Carbazoles, name is 9-(4-Fluorophenyl)-9H-carbazole, and the molecular formula is C7H5Cl2NO, HPLC of Formula: 57103-14-7.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Zhang, Yan published the artcileObservation of parecoxib sodium combined with midazolam in prevention of restlessness after endoscopic surgery, Computed Properties of 198470-85-8, the publication is Zhongguo Linchuang Yanjiu (2014), 27(3), 316-318, database is CAplus.

Objective To observe the effect of parecoxib sodium combined with small dose of midazolam in prevention of restlessness after endoscopic surgery. Random 90 patients receiving general anesthesia for elective endoscopic sinus surgery were divided into P, PM, C groups with 30 cases in each group, and before the end of 30 min of endoscopic sinus surgery, P group was given i.v. parecoxib sodium 40 mg, PM group was given i.v. parecoxib sodium 40 mg + midazolam 0.02 mg/kg, and group C was given i.v. injection of saline. The breathing recovery time, eye opening time, extubation time; and MAP and HR values at extubation (T1) and 5 min (T2) after extubation and 10 min (T3) after extubation were detected, and the restlessness score (RS), Ramasay sedation score (RSS), and visual analog scale (VAS) at postoperative 6h, 12h and 24h were recorded. Results The MAP and HR values at T1-T3 were superior in PM group (P<0.05); RS, RSS and VAS values at different time points in PM group were lower than P group and C group (P<0.05); the breathing recovery time, eye opening time and extubation time had no difference among the three groups (P>0.05). There were 14 cases of nausea and 11 cases of vomiting in C group; 12 cases of nausea and 9 cases of vomiting in P group; 8 cases of nausea and six cases of vomiting in PM group; nausea and vomiting was similar among the three groups (P>0.05). Conclusion Parecoxib combined with low-dose midazolam anesthesia may be effective in preventing endoscopic surgery restlessness, and can be safely used for analgesia after endoscopic sinus surgery.

Zhongguo Linchuang Yanjiu published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C6H17NO3Si, Computed Properties of 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Tao, Guanghua published the artcileApplication of dexmedetomidine combined with parecoxib sodium in pulmonary lobectomy with one-lung ventilation, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Jianyan Yixue Yu Linchuang (2016), 13(23), 3348-3351, database is CAplus.

Objective: To investigate the effect of dexmedetomidine combined with parecoxib sodium on pulmonary inflammatory response in patients undergoing pulmonary lobectomy with one-lung ventilation. Methods: Eighty patients underwent pulmonary lobectomy with one-lung ventilation were randomly divided into dexmedetomidine group (group D, n = 20), parecoxib sodium group (group P, n = 20), dexmedetomidine combined with parecoxib sodium group (D + P group, n = 20) and saline control group (N group, n = 20). The groups were treated with normal saline, dexmedetomidine, parecoxib sodium and dexmedetomidine combined with parecoxib sodium, resp. Peripheral venous blood was taken from the patients, and levels of interleukin (IL)-1β, IL-6, cyclooxygenase-2 (COX-2), reactive oxygen species (ROS) at different time points were detected by ELISA immunoassay. Radial arterial blood was taken from the patients and analyzed, and the partial pressure of blood oxygen (PaO₂), partial pressure of carbon dioxide (PaCO₂) and oxygenation index were compared. VAS pain score and analgesic dose were recorded at 12 h and 24 h after surgery. Results: The expression of inflammatory factors in D + P group was significantly lower than that in other groups, and that of the D group and P group were significantly less than that of N group (P < 0.05). The blood gas anal. showed that PaO₂ and oxygenation index in the D + P group were higher than those of the N group, while PaCO₂ is lower, and there is no statistically significant difference between the P group and D group (P > 0.05). In comparison of VAS score and 24 h tramadol dosage, the D + P group had the lowest VAS score and tramadol dosage, which were significantly lower than those of the N group (P < 0.05). Conclusion: Dexmedetomidine combined with parecoxib sodium can reduce intraoperative pulmonary inflammatory response, improve oxygenation and reduce the dose of postoperative analgesics in patients undergoing pulmonary lobectomy with one-lung ventilation.

Jianyan Yixue Yu Linchuang published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C8H8O3, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Xiong, Qiuju published the artcileEfficacy of continuous lumbar plexus block combined with multimodal analgesia after revision hip arthroplasty, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Chongqing Yike Daxue Xuebao (2017), 42(5), 560-564, database is CAplus.

Objective: To compare the analgesic efficacy between the continuous lumbar plexus block (CLPB) combining with multimodal analgesia and patient controlled i.v. analgesia (PCIA) combining with multimodal analgesia after revision hip arthroplasty. Methods: Totally 68 patients for single side revision hip arthroplasty were equally divided into CLPB group and PCIA group. The parecoxib was used in both group 3 days before operation. The ropivacaine was used to analgesia through lumbar plexus catheterization in CLPB group, and the PCIA group with tramadol and flurbiprofen analgesia. All patients continued analgesia for 3 days. After operation, the parecoxib was used when visual analog scale (VAS) scores more than 3 scores in exercise state. The VAS scores at rest and exercise state were estimated The parecoxib dose by i.v. injection and the presses of the pump were recorded. And the complications were observed Results: The VAS pain scores of CLPB group during rest at different time points after revision hip arthroplasty were significantly lower than those of PCIA group (P<0.05). The VAS scores of CLPB during exercise at 6 h, 12 h, 24 h after revision hip arthroplasty were (2.50±0.71), (3.59±0.99), (3.67±1.01), which were significantly lower than those of (4.97±0.94) (P=0.00), (4.85±0.86) (P=0.00), (4.32±0.73) (P=0.00) in PCIA group at corresponding time points. In CLPB group, the parecoxib dose by i.v. injection and presses of the pump were fewer than that of PCIA group (0.05). And the side effects of CLPB group were fewer than those in PCIA group. Conclusion: CLPB combined with multimodal analgesia can alleviate the early pain of patients undergoing revision hip arthroplasty; the patients who received CLPB technique showed better pain relief, less complication than those who been given PCIA. Therefore, CLPB combined with multimodal analgesia should be considered a better analgesia method for patients after revision hip arthroplasty.

Chongqing Yike Daxue Xuebao published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C8H13ClN2O, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Niu, Fu-guo published the artcileEffect of preemptive analgesia with parecoxib sodium on the inflammatory cytokine and stress in puerpera after cesarean section, Application of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Hainan Yixueyuan Xuebao (2016), 22(19), 2322-2324, 2328, database is CAplus.

Objective: To explore the effect of preemptive analgesia (PA) with parecoxib sodium on the inflammatory cytokine and stress in puerpera after cesarean section. Methods: A total of 70 pregnant women who were admitted in our hospital from May, 2015 to May, 2016 for cesarean section were included in the study and r andomized into the observation group and the control group with 35 cases in each group. A venous channel was established. The heart rate, blood pressure, and oxygen saturation were continuously monitored by the monitor. The patients in the observation group were i.v. injected with parecoxib sodium (40mg) and normal saline (2mL), while the patients in the control group were i.v. injected with normal saline (2mL) 30min before anesthesia induction. The venous blood when entering the operation room, after operation, 4h, 8h, and 12 hafter operation was extracted The plasma IL-6, TNF-α, P substance, E, and NE levels were detected. Results: IL-6 and TNF-α level after operation in the two groups were elevated, reached the peak 4hafter operation, and were gradually reduced 8hafter operation. IL-6 and TNF-α levels at each timing point after operation in the observation group were significantly lower than those in the control group (P < 0.05). P substance after operation in the two groups was elevated, reached the peak 4hafter operation, and was gradually reduced 8 h after operation. P substance level at each timing point after operation in the observation group was significantly lower than that in the control group (P < 0.05). N and NE levels after operation in the two groups were elevated, reached the peak 4h after operation, and were reduced to the levels when entering the operation time 12 hafter operation. N and NE levels at each timing point after operation in the observation group were significantly lower than those in the control group (P < 0.05). Conclusions: PA with parecoxib sodium in application of puerpera after cesarean section can effectively reduce the stress reaction, decrease the production of inflammatory cytokines, with a favorable analgesic effect, and further reduce the occurrence of postoperative complications.

Hainan Yixueyuan Xuebao published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Application of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem